Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems Webcast (2024)

This course will focus on specific topics discussed in the recent AUA Practice Guidelines for non-muscle invasive bladder cancer (NMIBC) and detail strategies to manage common clinical predicaments involved in the management of these tumors. The course will include short didactic lectures by each of the faculty but will focus predominantly on case presentations highlighting common and often perplexing topics in NMIBC. Specifically, we will focus on (1) important aspects of transurethral resection of bladder tumor (TURBT), (2) risk stratification for tumor recurrence and progression and use of cystectomy, (3) selection of the optimal intravesical agent at the right schedule, (4) current definitions of bacillus Calmette-Guérin (BCG)-refractory/-unresponsive/-relapsing disease and (5) drug and surgery options for BCG-unresponsive disease. Practical solutions will be presented that can be readily integrated into the office setting. Emphasis is placed on the evaluation of real clinical cases with open audience participation. 


This educational activity is supported by independent educational grants from:

Merck & Co., Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Implement current practice guidelines and explain methods and resources to improve TURBT skills.
  2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage.
  3. Identify methods to treat significant toxicities from various intravesical therapies.
  4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.
  5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Kamat, Ashish M.FKDScientific Study or TrialCurrent
PhotocureConsultant or AdvisorCurrent
TheralaseConsultant or AdvisorCurrent
MerckConsultant or AdvisorCurrent
BMSConsultant or AdvisorCurrent
ArquerConsultant or AdvisorCurrent
MedacConsultant or AdvisorCurrent
AsierisConsultant or Advisor12/31/2023
ImaginConsultant or AdvisorCurrent
EisaiConsultant or AdvisorCurrent
Cold GenesysConsultant or Advisor04/01/2023
Sessen BioConsultant or AdvisorCurrent
AdolorScientific Study or Trial01/01/2024
Heat BiologicsScientific Study or Trial04/01/2024
FerGeneScientific Study or TrialCurrent
AsierisConsultant or Advisor04/01/2023
Biological DynamicsConsultant or Advisor04/01/2023
Seattle GeneticsConsultant or AdvisorCurrent
ProTaraConsultant or AdvisorCurrent
Janssen PharmaceuticalConsultant or AdvisorCurrent
Incyte DSMBConsultant or AdvisorCurrent
UrogenConsultant or AdvisorCurrent
Biological DynamicsConsultant or Advisor04/01/2023
EngeneConsultant or AdvisorCurrent
RocheConsultant or AdvisorCurrent
FergeneConsultant or Advisor04/01/2023
Janssen (+Taris)Scientific Study or Trial12/31/2023
Seattle GeneticsScientific Study or Trial04/01/2023
ImvaxConsultant or AdvisorCurrent
CG OncologyConsultant or AdvisorCurrent
NonagenConsultant or AdvisorCurrent
CystotechConsultant or AdvisorCurrent
PfizerConsultant or AdvisorCurrent
Astellas PharmaConsultant or AdvisorCurrent
Vivet TherapeuticsConsultant or AdvisorCurrent
GenentechConsultant or AdvisorCurrent
Immunity BioConsultant or AdvisorCurrent
Pohar, Kamal S.PhotocureConsultant or AdvisorCurrent
MerckConsultant or Advisor03/14/2025
CG OncologyConsultant or AdvisorCurrent
Witjes, J. A.PhotocureConsultant or AdvisorCurrent
urogen; BMSConsultant or Advisor12/31/2022
JanssenConsultant or AdvisorCurrent
AstellasConsultant or AdvisorCurrent
MedacConsultant or AdvisorCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.